Viruses, Vol. 16, Pages 187: The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after Multiple Doses with the mRNA Pfizer & ndash;BioNTech Vaccine
Viruses, Vol. 16, Pages 187: The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after Multiple Doses with the mRNA Pfizer–BioNTech Vaccine
Viruses doi: 10.3390/v16020187
Authors:
Ana M. Espino
Albersy Armina-Rodriguez
Laura Alvarez
Carlimar Ocasio-Malavé
Riseilly Ramos-Nieves
Esteban I. Rodriguez Martinó
Paola López-Marte
Esther A. Torres
Carlos A. Sariol
The aim of this study was to analyze the profiles of IgG subclasses in COVID-19 convalescent Puerto Rican subjects and compare thes...
Source: Viruses - January 26, 2024 Category: Virology Authors: Ana M. Espino Albersy Armina-Rodriguez Laura Alvarez Carlimar Ocasio-Malav é Riseilly Ramos-Nieves Esteban I. Rodriguez Martin ó Paola L ópez-Marte Esther A. Torres Carlos A. Sariol Tags: Article Source Type: research
Short term Outcomes of COVID-19 Vaccines Among Lactating Mother and Child Dyads in Bangladesh: A Multi-centre, Cross-sectional Study
DiscussionThis large study of lactating woman-child dyads in Bangladesh, who received a diverse range of WHO-approved COVID-19 vaccines, showed no serious short-term adverse effects. (Source: Maternal and Child Health Journal)
Source: Maternal and Child Health Journal - January 22, 2024 Category: Health Management Source Type: research
Comparison of reporting rates of arthritis and arthralgia following AstraZeneca, Pfizer-BioNTech, Moderna, and Janssen vaccine administration against SARS-CoV-2 in 2021: analysis of European pharmacovigilance large-scale data
This study aimed to investigate the reporting rates of arthritis and arthralgia following the administration of four vaccines against SARS-CoV-2: Pfizer-BioNTech (Tozinameran), Moderna (CX-024414), AstraZeneca (Chadox1 NCOV-19), and Janssen (AD26.COV2.S) in 2021. We used data from the EudraVigilance database, specifically analyzing spontaneous reports of suspected adverse reactions (ADRs) from the European Union (EU)/European Economic Area (EEA) region. Age-group-specific reporting rates were calculated by dividing the number of arthralgia and arthritis reports per 1,000,000 vaccine doses administered per age group. Report...
Source: Rheumatology International - January 20, 2024 Category: Rheumatology Source Type: research
